摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

乙基6H-1,2-恶嗪-3-羧酸酯 | 185223-40-9

中文名称
乙基6H-1,2-恶嗪-3-羧酸酯
中文别名
——
英文名称
Ethyl 6H-1,2-oxazine-3-carboxylate
英文别名
ethyl 6H-oxazine-3-carboxylate
乙基6H-1,2-恶嗪-3-羧酸酯化学式
CAS
185223-40-9
化学式
C7H9NO3
mdl
——
分子量
155.153
InChiKey
VEDAJFIVJOLMQU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    47.9
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:665747b8a789f4c3acfc42ab5bce1dda
查看

反应信息

  • 作为反应物:
    描述:
    乙基6H-1,2-恶嗪-3-羧酸酯potassium permanganate 、 magnesium sulfate 作用下, 以 乙醇 为溶剂, 反应 0.5h, 生成 (4S,5R)-4,5-Dihydroxy-5,6-dihydro-4H-[1,2]oxazine-3-carboxylic acid ethyl ester
    参考文献:
    名称:
    Stereoselective Preparation of 4,5-Dihydroxy-5,6-dihydro-4H-1,2-oxazines and Their Derivatives
    摘要:
    cis-Dihydroxylation of 6H-1,2-oxazines 1 proceeds efficiently either by potassium permanganate at low temperature (Method A) or by ruthenium trichloride/sodium periodate at 0-5 degrees C (Method B). The resulting 4,5-dihydroxylated 1,2-oxazines 2 were usually obtained as diastereomerically pure compounds with the two newly introduced hydroxy groups positioned trans to the 6-alkoxy group. These products can be protected by standard methods either as acetals 4 or as diacetoxy compounds 5. In addition, the bicyclic orthoesters 7 and 8, dimesylates 15, and cyclic sulfates 19 have been prepared. First experiments dealing with transformations of the oxygen functionalities are described.
    DOI:
    10.1055/s-1999-3524
  • 作为产物:
    参考文献:
    名称:
    通过Heck环化作用的吲哚-3-丙酮酸肟醚和噻吩类似物。在合成硫氨酸-色氨酸中的应用
    摘要:
    Ñ的-allylation Ñ -BOC取代ø碘苯胺(14A-E )和thienoamines(16,18,20)采用乙基的甲基或苄基的肟醚(E)-2-氧代-5-溴-3-戊烯酸酯2A然后,钯催化的Heck环化反应生成Bz取代的乙基吲哚-3-丙酮酸酯(15a-f)和噻吩并吡咯(17,19,21–23)的肟醚。尝试将2a转化为相应的甲苯磺隆hydr或肟导致形成哒嗪(10)和恶嗪(13)衍生产品。通过还原肟双键,从相应的甲基肟醚中获得作为乙基酯的噻吨-色氨酸的三种可能的异构体。
    DOI:
    10.1016/0040-4020(96)00909-x
点击查看最新优质反应信息

文献信息

  • Stereoselective Preparation of 4,5-Dihydroxy-5,6-dihydro-4H-1,2-oxazines and Their Derivatives
    作者:Reinhold Zimmer
    DOI:10.1055/s-1999-3524
    日期:1999.7
    cis-Dihydroxylation of 6H-1,2-oxazines 1 proceeds efficiently either by potassium permanganate at low temperature (Method A) or by ruthenium trichloride/sodium periodate at 0-5 degrees C (Method B). The resulting 4,5-dihydroxylated 1,2-oxazines 2 were usually obtained as diastereomerically pure compounds with the two newly introduced hydroxy groups positioned trans to the 6-alkoxy group. These products can be protected by standard methods either as acetals 4 or as diacetoxy compounds 5. In addition, the bicyclic orthoesters 7 and 8, dimesylates 15, and cyclic sulfates 19 have been prepared. First experiments dealing with transformations of the oxygen functionalities are described.
  • Indole-3-pyruvic acid oxime ethers and thieno analogues by Heck cyclisation. Application to the synthesis of thia-tryptophans
    作者:David Wensbo、Salo Gronowitz
    DOI:10.1016/0040-4020(96)00909-x
    日期:1996.11
    thienoamines (16,18,20) employing methyl or benzyl oxime ethers of ethyl (E)-2-oxo-5-bromo-3-pentenoate 2a, followed by palladium-catalysed Heck cyclisation yielded oxime ethers of Bz-substituted ethyl indole-3-pyruvates (15a-f) and thienopyrroles (17,19,21–23). Attempted conversion of 2a into the corresponding tosyl hydrazone or oxime resulted in formation of pyridazine (10) and oxazine (13) derivatives.
    Ñ的-allylation Ñ -BOC取代ø碘苯胺(14A-E )和thienoamines(16,18,20)采用乙基的甲基或苄基的肟醚(E)-2-氧代-5-溴-3-戊烯酸酯2A然后,钯催化的Heck环化反应生成Bz取代的乙基吲哚-3-丙酮酸酯(15a-f)和噻吩并吡咯(17,19,21–23)的肟醚。尝试将2a转化为相应的甲苯磺隆hydr或肟导致形成哒嗪(10)和恶嗪(13)衍生产品。通过还原肟双键,从相应的甲基肟醚中获得作为乙基酯的噻吨-色氨酸的三种可能的异构体。
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol